Article citationsMore>>
Goetz, M.P., Rae, J.M., Suman, V.J., Safgren, S.L., Ames, M.M., Visscher, D.W., Reynolds, C., Couch, F.J., Lingle, W.L., Flockhart, D.A., Desta, Z., Perez, E.A. and Ingle, J.N. (2005) Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. Journal of Clinical Oncology, 23, 9312-9318. doi:10.1200/JCO.2005.03.3266
has been cited by the following article:
-
TITLE:
More Stable, More Estrogenic: The SERM-ERα LBD Complex
AUTHORS:
Li Gao, Yaoquan Tu, Leif A. Eriksson
KEYWORDS:
Breast Cancer; Tamoxifen Resistance; Molecular Dynamics Simulations;
Dihydrobenzoxathiin; SERM
JOURNAL NAME:
Journal of Biophysical Chemistry,
Vol.2 No.3,
August
9,
2011
ABSTRACT: Many synthetic selective estrogen receptor modulators (SERMs) have been cocrystallized with the human estrogen receptor α ligand binding domain (ERα LBD). Despite stabilizing the same canonical inactive conformation of the LBD, most SERMs display different ligand-dependent pharmacological profiles. We show here that increased partial agonism of SERMs is associated with increased conformational stability of the SERM-LBD complexes, by investigation of dihydrobenzoxathiin-based SERMs using molecular modelling techniques. Analyses of tamoxifen (TAM) and 4-hydroxytamoxifen (OHT) in complex with the LBD furthermore indicates that the conversion of TAM to OHT increases both the affinity to ERα and the partial agonism of the anti-cancer drug, which provides a plausible explanation of the counterintuitive results of TAM therapy.
Related Articles:
-
Takanori Ayabe, Masaki Tomita, Eiichi Chosa, Hiroki Mori, Kunihide Nakamura
-
Lama S. Alfehaid, Abdulmalik S. Alotaibi, Ahmed S. Alanazi, Rami T. Bustami, Razan El Melik
-
Jillian L. Capodice, Philippa Cheetham, Mitchell C. Benson, James M. McKiernan, Aaron E. Katz
-
Lilian Hamity, Franco Ramello, Leandro Marani, Alejandro Moyano, Eduardo Moreyra, Luis E. Alday
-
I. A. El-Mesady, G.M. Saleh, N. E. Khaled, A. A. Hussein, H. M. El-Samman, Kh. K. Abd-Al Aziz